"If we can proceed with an 510(k) filing, our best estimate at this time is that it could take four to six months, possibly longer, for the FDA to clear our 510(k) application. Once cleared by the FDA the First Warning System could immediately commence commercialization.

"We have had many questions from shareholders and interested parties concerning the status of our FDA filing; we ask that they continue to be patient along with us. As soon as the FDA's response is received, we will make a press release and post the response on Lifeline's website.

"We've also received many questions concerning the prospect of a reverse split of the common stock. Even though the outstanding common stock is approximately 2.9 billion shares, we have no plans for a reverse split."

((Comments on this story may be sent to health@closeupmedia.com))

"If we can proceed with an 510(k) filing, our best estimate at this time is that it could take four to six months, possibly longer, for the FDA to clear our 510(k) application. Once cleared by the FDA the First Warning System(TM) could immediately commence commercialization.

"We have had many questions from shareholders and interested parties concerning the status of our FDA filing; we ask that they continue to be patient along with us. As soon as the FDA's response is received, we will make a press release and post the response on Lifeline's website.

"We've also received many questions concerning the prospect of a reverse split of the common stock. Even though the outstanding common stock is approximately 2.9 billion shares, we have no plans for a reverse split."

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, the ability to obtain financing, successful development of the Company's product or market acceptance of the product and regulatory and shareholder approval for anticipated actions.

SOURCE: Lifeline Biotechnologies, Inc.

Lifeline Biotechnologies, Inc. 
Jim Holmes, 775-324-1933 
Jholmes@lbti.com 
www.lbti.com

"We have had questions on our current FDA filing. We await the FDA's response, which could be received as early as the end of September. However, that is probably optimistic and it could be some additional 30 to 45 days before we receive the FDA's response. As soon as we have the response we expect to release the information to the public.

"We've also received many questions concerning the prospect of a reverse split of the common stock. We have no plans to reverse split Lifeline's common stock."

More Information:

www.pinksheets.com

((Comments on this story may be sent to health@closeupmedia.com))

"We have had questions on our current FDA filing. We await the FDA's response, which could be received as early as the end of September. However, that is probably optimistic and it could be some additional 30 to 45 days before we receive the FDA's response. As soon as we have the response we expect to release the information to the public.

"We've also received many questions concerning the prospect of a reverse split of the common stock. We have no plans to reverse split Lifeline's common stock."

Save Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, the ability to obtain financing, successful development of the Company's product or market acceptance of the product and regulatory and shareholder approval for anticipated actions.

SOURCE: Lifeline Biotechnologies, Inc.

Lifeline Biotechnologies, Inc. 
Jim Holmes, 775-324-1933 
Jholmes@lbti.com 
www.lbti.com